410 related articles for article (PubMed ID: 25885010)
1. Comorbid anxiety and social avoidance in treatment of severe childhood aggression: response to adding risperidone to stimulant and parent training; mediation of disruptive symptom response.
Arnold LE; Gadow KD; Farmer CA; Findling RL; Bukstein O; Molina BS; Brown NV; Li X; Rundberg-Rivera EV; Bangalore S; Buchan-Page K; Hurt EA; Rice R; McNamara NK; Aman MG
J Child Adolesc Psychopharmacol; 2015 Apr; 25(3):203-12. PubMed ID: 25885010
[TBL] [Abstract][Full Text] [Related]
2. Comorbid symptomatology moderates response to risperidone, stimulant, and parent training in children with severe aggression, disruptive behavior disorder, and attention-deficit/hyperactivity disorder.
Farmer CA; Brown NV; Gadow KD; Arnold LE; Kolko DG; Findling RL; Molina BS; Buchan-Page KA; Rice RR; Bangalore SS; Bukstein O; Rundberg-Rivera EV; McNamara N; Aman MG
J Child Adolesc Psychopharmacol; 2015 Apr; 25(3):213-24. PubMed ID: 25885011
[TBL] [Abstract][Full Text] [Related]
3. Participant satisfaction in a study of stimulant, parent training, and risperidone in children with severe physical aggression.
Rundberg-Rivera EV; Townsend LD; Schneider J; Farmer CA; Molina BB; Findling RL; Gadow KD; Bukstein OG; Arnold LE; Kolko DJ; Buchan-Page KA; McNamara NK; Michel C; Austin A; Kipp H; Rice RR; Aman MG
J Child Adolesc Psychopharmacol; 2015 Apr; 25(3):225-33. PubMed ID: 25885012
[TBL] [Abstract][Full Text] [Related]
4. The Treatment of Severe Childhood Aggression Study: 12 Weeks of Extended, Blinded Treatment in Clinical Responders.
Findling RL; Townsend L; Brown NV; Arnold LE; Gadow KD; Kolko DJ; McNamara NK; Gary DS; Kaplin DB; Farmer CA; Kipp H; Williams C; Butter EM; Bukstein OG; Rice R; Buchan-Page K; Molina BS; Aman MG
J Child Adolesc Psychopharmacol; 2017 Feb; 27(1):52-65. PubMed ID: 28212067
[TBL] [Abstract][Full Text] [Related]
5. What does risperidone add to parent training and stimulant for severe aggression in child attention-deficit/hyperactivity disorder?
Aman MG; Bukstein OG; Gadow KD; Arnold LE; Molina BS; McNamara NK; Rundberg-Rivera EV; Li X; Kipp H; Schneider J; Butter EM; Baker J; Sprafkin J; Rice RR; Bangalore SS; Farmer CA; Austin AB; Buchan-Page KA; Brown NV; Hurt EA; Grondhuis SN; Findling RL
J Am Acad Child Adolesc Psychiatry; 2014 Jan; 53(1):47-60.e1. PubMed ID: 24342385
[TBL] [Abstract][Full Text] [Related]
6. Risperidone added to parent training and stimulant medication: effects on attention-deficit/hyperactivity disorder, oppositional defiant disorder, conduct disorder, and peer aggression.
Gadow KD; Arnold LE; Molina BS; Findling RL; Bukstein OG; Brown NV; McNamara NK; Rundberg-Rivera EV; Li X; Kipp HL; Schneider J; Farmer CA; Baker JL; Sprafkin J; Rice RR; Bangalore SS; Butter EM; Buchan-Page KA; Hurt EA; Austin AB; Grondhuis SN; Aman MG
J Am Acad Child Adolesc Psychiatry; 2014 Sep; 53(9):948-959.e1. PubMed ID: 25151418
[TBL] [Abstract][Full Text] [Related]
7. Attendance and Engagement in Parent Training Predict Child Behavioral Outcomes in Children Pharmacologically Treated for Attention-Deficit/Hyperactivity Disorder and Severe Aggression.
Joseph HM; Farmer C; Kipp H; Kolko D; Aman M; McGinley J; Arnold LE; Gadow KD; Findling RL; Molina BSG
J Child Adolesc Psychopharmacol; 2019 Mar; 29(2):90-99. PubMed ID: 30592635
[TBL] [Abstract][Full Text] [Related]
8. Severely Aggressive Children Receiving Stimulant Medication Versus Stimulant and Risperidone: 12-Month Follow-Up of the TOSCA Trial.
Gadow KD; Brown NV; Arnold LE; Buchan-Page KA; Bukstein OG; Butter E; Farmer CA; Findling RL; Kolko DJ; Molina BS; Rice RR; Schneider J; Aman MG
J Am Acad Child Adolesc Psychiatry; 2016 Jun; 55(6):469-78. PubMed ID: 27238065
[TBL] [Abstract][Full Text] [Related]
9. Risperidone effects in the presence/absence of psychostimulant medicine in children with ADHD, other disruptive behavior disorders, and subaverage IQ.
Aman MG; Binder C; Turgay A
J Child Adolesc Psychopharmacol; 2004; 14(2):243-54. PubMed ID: 15319021
[TBL] [Abstract][Full Text] [Related]
10. Atypical antipsychotics for disruptive behaviour disorders in children and youths.
Loy JH; Merry SN; Hetrick SE; Stasiak K
Cochrane Database Syst Rev; 2012 Sep; (9):CD008559. PubMed ID: 22972123
[TBL] [Abstract][Full Text] [Related]
11. Clinical Implications From the Treatment of Severe Childhood Aggression (TOSCA) Study: A Re-Analysis and Integration of Findings.
Barterian JA; Arnold LE; Brown NV; Farmer CA; Williams C; Findling RL; Kolko DJ; Bukstein OG; Molina BSG; Townsend L; Aman MG
J Am Acad Child Adolesc Psychiatry; 2017 Dec; 56(12):1026-1033. PubMed ID: 29173736
[TBL] [Abstract][Full Text] [Related]
12. Atypical antipsychotics for disruptive behaviour disorders in children and youths.
Loy JH; Merry SN; Hetrick SE; Stasiak K
Cochrane Database Syst Rev; 2017 Aug; 8(8):CD008559. PubMed ID: 28791693
[TBL] [Abstract][Full Text] [Related]
13. Risperidone Added to Psychostimulant in Children with Severe Aggression and Attention-Deficit/Hyperactivity Disorder: Lack of Effect on Attention and Short-Term Memory.
Farmer CA; Epstein JN; Findling RL; Gadow KD; Arnold LE; Kipp H; Kolko DJ; Butter E; Schneider J; Bukstein OG; McNamara NK; Molina BS; Aman MG
J Child Adolesc Psychopharmacol; 2017 Mar; 27(2):117-124. PubMed ID: 27348211
[TBL] [Abstract][Full Text] [Related]
14. The influence of risperidone on attentional functions in children and adolescents with attention-deficit/hyperactivity disorder and co-morbid disruptive behavior disorder.
Günther T; Herpertz-Dahlmann B; Jolles J; Konrad K
J Child Adolesc Psychopharmacol; 2006 Dec; 16(6):725-35. PubMed ID: 17201616
[TBL] [Abstract][Full Text] [Related]
15. Standardized Observation Analogue Procedure in the Treatment of Severe Childhood Aggression Study.
Grondhuis SN; Farmer CA; Arnold LE; Gadow KD; Findling RL; Molina BSG; Kolko DJ; Buchan-Page KA; Rice RR; Butter EM; Aman MG
J Child Adolesc Psychopharmacol; 2020 Feb; 30(1):48-54. PubMed ID: 31730370
[No Abstract] [Full Text] [Related]
16. Combination use of atomoxetine hydrochloride and olanzapine in the treatment of attention-deficit/hyperactivity disorder with comorbid disruptive behavior disorder in children and adolescents 10-18 years of age.
Holzer B; Lopes V; Lehman R
J Child Adolesc Psychopharmacol; 2013 Aug; 23(6):415-8. PubMed ID: 23952189
[TBL] [Abstract][Full Text] [Related]
17. A Naturalistic Comparison of Methylphenidate and Risperidone Monotherapy in Drug-Naive Youth With Attention-Deficit/Hyperactivity Disorder Comorbid With Oppositional Defiant Disorder and Aggression.
Masi G; Manfredi A; Nieri G; Muratori P; Pfanner C; Milone A
J Clin Psychopharmacol; 2017 Oct; 37(5):590-594. PubMed ID: 28806385
[TBL] [Abstract][Full Text] [Related]
18. Long-term safety and efficacy of risperidone for the treatment of disruptive behavior disorders in children with subaverage IQs.
Turgay A; Binder C; Snyder R; Fisman S
Pediatrics; 2002 Sep; 110(3):e34. PubMed ID: 12205284
[TBL] [Abstract][Full Text] [Related]
19. Effects of risperidone on conduct and disruptive behavior disorders in children with subaverage IQs.
Snyder R; Turgay A; Aman M; Binder C; Fisman S; Carroll A;
J Am Acad Child Adolesc Psychiatry; 2002 Sep; 41(9):1026-36. PubMed ID: 12218423
[TBL] [Abstract][Full Text] [Related]
20. Risperidone augmentation for treatment-resistant aggression in attention-deficit/hyperactivity disorder: a placebo-controlled pilot study.
Armenteros JL; Lewis JE; Davalos M
J Am Acad Child Adolesc Psychiatry; 2007 May; 46(5):558-565. PubMed ID: 17450046
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
